In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
about
In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanismsEfficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.Telithromycin- and fluoroquinolone-resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and beta-lactams: SMART program 2001 data.Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.Telithromycin: a novel agent for the treatment of community-acquired upper respiratory infectionsMutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolidesIn vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanismsDiversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.Pneumococcal resistance: the treatment challenge.Telithromycin: an oral ketolide for respiratory infections.Telithromycin: the first of the ketolides.In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis.Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in GermanyHigh-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniaeTelithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumoniaTemporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006Emergence and spread of cfr-mediated multiresistance in staphylococci: an interdisciplinary challenge.In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae.In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologiesAntipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.Antibiotic resistance: where do ketolides fit?Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin.In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
P2860
Q24653865-CF3A58FE-E345-4AD8-B4EF-573ED4BE6ACBQ24813259-F4793809-EEDB-46BB-BA51-AC04F3AA4F2DQ31936145-7A2BA8A7-4D6B-4D54-AF20-DC46EE12EEE9Q33187513-954DD033-9FC5-4A3C-9765-105405B6E112Q33883600-3B187262-7C3A-45DA-BB05-D9C1259796DFQ33945038-DAD01C51-8FB1-46F4-B6EF-0C32E56F71ECQ33980212-C9719C28-16C9-4A31-A220-24ED70A4A727Q33982593-49A8E7A8-5B37-4E70-8E21-7C31E32C29B2Q33982849-F84CE720-2542-4733-A858-AB218A41C404Q34104600-4A64AF61-E1AA-416C-8B4C-82C692A7DE9FQ34219099-AE84FA7B-2EB1-4ECE-AF9E-BF2AC67688E1Q34401542-1595178F-6788-42C5-B890-427934276CABQ34564295-C75E6C88-6210-4C5E-94A7-22AC1D7FA55FQ35014167-E59B6298-361B-4D32-852D-8BF6DAC571F1Q35047705-168CC766-6520-46A0-930D-7132A589E676Q35103781-42180262-1FF3-4F81-8939-2EA7B20B1F41Q35647682-2CA853F6-93ED-4BB4-B641-AA4F08122DEFQ37116814-97BC38E6-2764-4C75-B9DF-BBC41CDF6207Q37190726-444E3E51-B5DD-4698-AD5C-EFCDE5E571C9Q37921295-A195317A-E21F-43FC-A70A-C1D677B682D9Q39476686-FB2664B3-2288-4955-A6C5-7D3864DBA486Q39652872-33EA7079-7DA6-4917-8D57-0C91A6F73A63Q40290408-3CC34443-37C9-4C09-9D6A-D7009EF28AC3Q40469366-2D81EC23-A486-41CA-BC7B-E5D3BE397395Q41838198-14D5FF87-9846-44BF-A8B7-D3543ED34958Q42112086-B382461D-5C96-4C6F-8A07-D9E37AF51ED4Q42112713-8BFAC5B3-B145-49EA-AFA9-CC13073FE264Q43595556-60B697ED-E0DC-474D-8BB6-FF79DC13237EQ46168968-76167AC3-AFD9-43D2-AFBF-8FA2A3B658B4Q46514173-3D968764-6B86-41BE-AFE1-A5BDEC2AA132
P2860
In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro development of resist ...... in in Streptococcus pneumoniae
@ast
In vitro development of resist ...... in in Streptococcus pneumoniae
@en
type
label
In vitro development of resist ...... in in Streptococcus pneumoniae
@ast
In vitro development of resist ...... in in Streptococcus pneumoniae
@en
prefLabel
In vitro development of resist ...... in in Streptococcus pneumoniae
@ast
In vitro development of resist ...... in in Streptococcus pneumoniae
@en
P2093
P2860
P1476
In vitro development of resist ...... in in Streptococcus pneumoniae
@en
P2093
B E Dewasse
M R Jacobs
P C Appelbaum
T A Davies
P2860
P304
P356
10.1128/AAC.44.2.414-417.2000
P407
P577
2000-02-01T00:00:00Z